Skip to main content

Recent News

Dr. John Cush
@RheumNow
New FDA Approved for Polymyalgia Rheumatica - Secukinumab The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Dr. John Cush
@RheumNow
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. https://t.co/br5LBqkqeu
Dr. John Cush
@RheumNow
Conducting a CAR-T Trial: A Pediatric Rheumatologist’s Reflections At #ACR26, a scientific session titled “Program and Ethical Readiness in Pediatric Rheumatology: Building CAR Therapy Pathways for Rare Disease Care” addressed our readiness as a field for CAR-based therapies. https://t.co/qYWKJtTxmZ

Sjögren’s and SOB? Think About ILD!

Daric A. Mueller, PA-C

ILD is a particularly worrisome systemic feature of SjD that may be associated with poorer quality of life outcomes and increased mortality. Prevalence of SjD-ILD has been quoted to occur in 10-20% of SjD patients; however, identification of SjD may vary widely based on the testing methodologies used.

Dr. John Cush
@RheumNow
Top 6 Practice-Changing Highlights from ACR26 The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance. Here is our https://t.co/JmRpPh8Wzi
Dr. John Cush
@RheumNow
Does a Gout Flare Increase Risk of a Cardiovascular Event? In 2022, Cipolletta and colleagues published a JAMA study showing a temporal association between gout flares and subsequent major adverse cardiovascular events (MACE). This study reported 93% higher odds of MACE in the https://t.co/G91c9oz7tP

New FDA Approved for Polymyalgia Rheumatica - Secukinumab

Jack Cush, MD

Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for people living with PMR. 

×